These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7055936)

  • 21. Characterization of middle molecule compounds.
    Zimmerman L; Jörnvall H; Bergström J; Fürst P; Sjövall J
    Artif Organs; 1981; 4 Suppl():33-6. PubMed ID: 7295092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isotachophoretic pattern of LDH inhibiting fractions obtained from uremic ultrafiltrate by gelchromatography.
    De Smet R; van Landschoot N; van der Stiggel G; Ringoir S
    Int J Artif Organs; 1983 Mar; 6(2):67-70. PubMed ID: 6840893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of middle molecules in uremic patients.
    Wu ZG; Cai ZH; Lu ZN; Liao LT; Zhu SQ
    Chin Med J (Engl); 1985 Feb; 98(2):115-20. PubMed ID: 3922688
    [No Abstract]   [Full Text] [Related]  

  • 24. Medium-sized peptides in the blood of patients with uremia.
    Mabuchi H; Nakahashi H
    Nephron; 1983; 33(4):232-7. PubMed ID: 6843753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A gas chromatographic-mass spectrometric analysis of organic acids in uremic ultrafiltrate (author's transl)].
    Maeda K; Niwa T; Kobayashi K
    Nihon Jinzo Gakkai Shi; 1981 Jan; 23(1):75-88. PubMed ID: 7289205
    [No Abstract]   [Full Text] [Related]  

  • 26. Fluorescent substances in uremic and normal serum.
    Shaykh M; Bazilinski N; McCaul DS; Ahmed S; Dubin A; Musiala T; Dunea G
    Clin Chem; 1985 Dec; 31(12):1988-92. PubMed ID: 4064287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Separation and characterization of uremic metabolites in biologic fluids: a screening approach to the definition of uremic toxins.
    Gordon A; Berström J; Fürst P; Zimmerman L
    Kidney Int Suppl; 1975 Jan; (2):45-51. PubMed ID: 1057692
    [No Abstract]   [Full Text] [Related]  

  • 28. Many hitherto unknown peptides are principal constituents of uremic "middle molecules".
    Menyhárt J; Gróf J
    Clin Chem; 1981 Oct; 27(10):1712-6. PubMed ID: 7285323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Search for peptidic "middle molecules" in uremic sera: isolation and chemical identification of fibrinogen fragments.
    Kaplan B; Cojocaru M; Unsworth E; Knecht A; Martin BM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Oct; 796(1):141-53. PubMed ID: 14552825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Profiling of uremic serum by high-resolution gas chromatography-electron-impact, chemical ionization mass spectrometry.
    Schoots AC; Mikkers FE; Cramers CA; Ringoir S
    J Chromatogr; 1979 Sep; 164(1):1-8. PubMed ID: 541389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening of UV-absorbing solutes in uremic serum by reversed phase HPLC--change of blood levels in different therapies.
    Schoots AC; Homan HR; Gladdines MM; Cramers CA; de Smet R; Ringoir SM
    Clin Chim Acta; 1985 Feb; 146(1):37-51. PubMed ID: 3987038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uremic toxins and the elusive middle molecules.
    Schoots A; Mikkers F; Cramers C; de Smet R; Ringoir S
    Nephron; 1984; 38(1):1-8. PubMed ID: 6472528
    [No Abstract]   [Full Text] [Related]  

  • 33. Amino acid containing compounds in uremic serum-search for middle molecules by high performance liquid chromatography.
    Kaplan B; Gotfried M; Ravid M
    Clin Nephrol; 1986 Aug; 26(2):66-71. PubMed ID: 3757315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma.
    Andress DL; Howard GA; Birnbaum RS
    Kidney Int; 1991 May; 39(5):942-5. PubMed ID: 2067211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accumulation of furancarboxylic acids in uremic serum as inhibitors of drug binding.
    Niwa T; Takeda N; Maeda K; Shibata M; Tatematsu A
    Clin Chim Acta; 1988 Apr; 173(2):127-38. PubMed ID: 3378354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate.
    Ringoir SM; van Landschoot N; de Smet R
    Clin Nephrol; 1980 Mar; 13(3):109-12. PubMed ID: 7379359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of dialysis treatment in uremic patients by gel filtration of serum.
    Osada J; Gea T; Sanz C; Millan I; Botella J
    Clin Chem; 1990 Nov; 36(11):1906-10. PubMed ID: 2242568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversed-phase liquid-chromatographic analysis of hemodialysate from uremic patients.
    Senftleber FC; Halline AG; Veening H; Dayton DA
    Clin Chem; 1976 Sep; 22(9):1522-7. PubMed ID: 8223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolation of an immunosuppressive fraction in ultrafiltrate from uremic sera.
    Navarro J; Grossetete MC; Defrasne A; Touraine JL; Traeger J
    Nephron; 1985; 40(4):396-400. PubMed ID: 4022207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Isolation, structure elucidation and synthesis of a hexapeptide from the hemodialysate of uremic patients].
    Bovermann G; Rautenstrauch H; Seybold G; Jung G
    Hoppe Seylers Z Physiol Chem; 1982 Oct; 363(10):1187-202. PubMed ID: 7141402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.